Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: 10.1038/s41467-018-07472-8
- Event
-
Veröffentlichung
- (where)
-
Aachen
- (who)
-
Universitätsbibliothek der RWTH Aachen
- (when)
-
2018
- Creator
-
Santana-Codina, Naiara
Roeth, Anjali Anna Joy
Zhang, Yi
Yang, Annan
Mashadova, Oksana
Asara, John M.
Wang, Xiaoxu
Bronson, Roderick T.
Lyssiotis, Costas A.
Ying, Haoqiang
Kimmelman, Alec C.
- DOI
-
10.18154/RWTH-CONV-240469
- URN
-
urn:nbn:de:101:1-2024010500383963322599
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:41 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Santana-Codina, Naiara
- Roeth, Anjali Anna Joy
- Zhang, Yi
- Yang, Annan
- Mashadova, Oksana
- Asara, John M.
- Wang, Xiaoxu
- Bronson, Roderick T.
- Lyssiotis, Costas A.
- Ying, Haoqiang
- Kimmelman, Alec C.
- Universitätsbibliothek der RWTH Aachen
Time of origin
- 2018
Other Objects (12)
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS renders cells resistant to ferroptosis by upregulating FSP1
Oncogenic KrasG12D causes myeloproliferation in leukaemia via NLRP3 inflammasome activation
TP53-status dependent oncogenic EZH2 Activity in Pancreatic Cancer
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Evolutionary trajectories and KRAS dosage define pancreatic cancer phenotypes
Characterization of KRAS-driven epigenomic changes in pancreatic carcinogenesis
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
The role of oncogenic Kras signaling in the non-hematopoietic bone marrow microenvironment
Influence of mitochondrial thioredoxin reductase on KrasG12D-mediated pancreatic carcinogenesis
PDEδ interference impedes the proliferation and survival of oncogenic KRas expressing human cancer cell lines
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS renders cells resistant to ferroptosis by upregulating FSP1
Oncogenic KrasG12D causes myeloproliferation in leukaemia via NLRP3 inflammasome activation
TP53-status dependent oncogenic EZH2 Activity in Pancreatic Cancer
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Evolutionary trajectories and KRAS dosage define pancreatic cancer phenotypes
Characterization of KRAS-driven epigenomic changes in pancreatic carcinogenesis
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
The role of oncogenic Kras signaling in the non-hematopoietic bone marrow microenvironment
Influence of mitochondrial thioredoxin reductase on KrasG12D-mediated pancreatic carcinogenesis
PDEδ interference impedes the proliferation and survival of oncogenic KRas expressing human cancer cell lines
Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
Oncogenic KRAS renders cells resistant to ferroptosis by upregulating FSP1
Oncogenic KrasG12D causes myeloproliferation in leukaemia via NLRP3 inflammasome activation
TP53-status dependent oncogenic EZH2 Activity in Pancreatic Cancer
Targeting mutant KRAS in pancreatic cancer: futile or promising?
Evolutionary trajectories and KRAS dosage define pancreatic cancer phenotypes
Characterization of KRAS-driven epigenomic changes in pancreatic carcinogenesis
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
The role of oncogenic Kras signaling in the non-hematopoietic bone marrow microenvironment
Influence of mitochondrial thioredoxin reductase on KrasG12D-mediated pancreatic carcinogenesis